Lixte Total Debt To Capitalization from 2010 to 2024
| LIXTW Stock | USD 0.03 0.0002 0.71% |
Total Debt To Capitalization | First Reported 2010-12-31 | Previous Quarter (0.40) | Current Value (0.42) | Quarterly Volatility 0.01366855 |
Check Lixte Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lixte Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 17 K, Other Operating Expenses of 2.7 M or EBITDA of 3.4 K, as well as many indicators such as Price To Sales Ratio of 9.35, Dividend Yield of 0.0011 or PTB Ratio of 1.18. Lixte financial statements analysis is a perfect complement when working with Lixte Biotechnology Valuation or Volatility modules.
Lixte | Total Debt To Capitalization |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.